HIV Infection
Conditions
Keywords
Dipyridamole, HIV, Immune Markers, Immune Activation, Inflammation
Brief summary
The purpose of this study is to determine if Dipyridamole (DP) will decrease inflammation in HIV-1-infected individuals who are already on antiretroviral treatment and have a low viral load.
Detailed description
Background: * Since HIV-infected individuals started taking anti-HIV medications, illnesses from AIDS have decreased, but other serious diseases have increased. Researchers think this may be caused by an increase in activity of the immune system that fights infection, leading to inflammation. Inflammation is a normal body reaction to any infection. However, if inflammation lasts a long time, like in HIV infection, it may lead to complications such as heart disease, cancer, liver disease, lung disease, and problems with thinking. Many HIV researchers are studying the harmful effects of this prolonged immune system activity and inflammation and possible ways to prevent these complications. * A drug called dipyridamole is approved by the Food and Drug Administration (FDA) under the trade name Persantine® for use with other drugs to reduce the risk of blood clots after heart valve replacement. Laboratory studies have shown that dipyridamole also lowers the level of immune system activity and inflammation measured in the blood. Objectives: * To see how dipyridamole affects blood and lung tests to measure immune system activity and inflammation and to look at the safety and tolerability of dipyridamole in people infected with HIV. This use of dipyridamole is investigational, or not approved by the FDA; however, the dose to be used in this study, 100mg four times a day, is the dose approved by the FDA. Eligibility: * Individuals 18 years of age and older who have HIV infection and are taking medications to treat it, and have a low viral load (HIV-1 RNA \<50 copies/mL) for a minimum of 12 months. Design: * Participants will be screened with a physical exam, blood test, and medical history. Women of reproductive age will also receive a pregnancy test. * Participants will take either Dipyridamole or a placebo for 12 weeks. Then they will take Dipyridamole for 12 weeks. * During the study, participants will have frequent blood and urine tests. Dipyridamole drug levels, and liver and kidney function tests will be performed. HIV viral load (the amount of virus in the blood) will also be studied. * Participants will have a final follow-up visit after an additional 4 weeks. * Four brachial artery ultrasound images will be taken. * Four pre- and post-bronchodilator spirometry tests will be performed by participants enrolled under Version 2.0: after each pre-test spirometry, participants will be asked to inhale 4 puffs of albuterol, and then to repeat the spirometry for post-testing. * Participants will receive rectal swabs at screening, and four flexible sigmoidoscopies with rectal biopsies of the sigmoid colon throughout the study. These studies of the lower colon and samples of the rectum will be used to explore the effects of Dipyridamole. Participants can, however, opt out of all rectal procedures.
Interventions
DRUGDipyridamole
Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
DRUGPlacebo, then Dipyridamole
Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Sharon Riddler
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load. * On ART for at least 12 months prior to study entry with a regimen that includes three or more antiretroviral medications. More information on this criterion is available in the protocol. * Plasma HIV-1 RNA \<50 copies/mL by any standard clinical assay at screening and for a minimum of 12 months prior to entry, confirmed by at least 2 measurements prior to study entry, one of which must be at least 48 weeks prior to study entry and one of which must be 61 days and 48 weeks prior to study entry. All plasma HIV-1 RNA measurements in the 12 months prior to study entry must be \<50 copies/mL (with the exception that a single detectable measurement of ≤ 200 copies/mL is permitted if the RNA levels immediately before and after are \<50 copies/mL). * Stable ART regimen for at least 8 weeks prior to study entry and no plans to change ART regimen for at least 6 months following study entry. * Ability and willingness to provide informed consent. * In the opinion of the investigator, no medical, mental health or other condition that precludes participation. * Laboratory values obtained within 60 days prior to entry. * Hemoglobin ≥10.0 g/dL * Platelet count ≥100,000/mm3 * INR ≤ 1.5 (for rectal tissue subset only) * PTT \<2x ULN (for rectal tissue subset only) * AST and ALT \< 2.5 x upper limit of normal (ULN) * Total bilirubin \< 2.5 x ULN (except if hyperbilirubinemia is secondary to atazanavir). * Creatinine ≤ 1.5 x ULN * Hepatitis B surface antigen negative * Hepatitis C antibody negative (note: subject with HCV Ab positive is eligible if Hepatitis C RNA PCR (viral load) is undetectable) * For females of reproductive potential, negative serum or urine pregnancy test at screening and within 72 hours prior to study entry. Females of reproductive potential include women who have not been post-menopausal for at least 24 consecutive months, (i.e., who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy). * Females of reproductive potential who are participating in sexual activity that could lead to pregnancy must agree to use one method of acceptable contraception while receiving protocol-specified treatment and for 4 weeks after stopping the treatment. These methods include condoms (male or female) with or without a spermicidal agent; diaphragm or cervical cap with spermicide; intrauterine device (IUD); and hormone-based contraceptive. * Females not of reproductive potential (girls who have not reached menarche, women who have been post-menopausal for at least 24 consecutive months, or women who have undergone surgical sterilization, e.g., hysterectomy, bilateral oophorectomy, or bilateral tubal ligation or salpingectomy) are eligible without requiring the use of a contraceptive. Self- report is acceptable documentation of sterilization, other contraceptive methods, and menopause. * Rectal Tissue Subset only: Willing to abstain from receptive anal intercourse and practices involving insertion of anything in the rectum (drug, enema, penis, or sex toy) for 72 hours prior to rectal biopsy and for 7 days post-biopsy to minimize risk of bleeding complications.
Exclusion criteria
* Pregnancy or breast-feeding. * Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation. * Known cardiovascular disease (history of MI, coronary artery bypass graft surgery, percutaneous coronary intervention, stroke, transient ischemic attack, peripheral arterial disease with ABI \<0.9 or claudication). * Uncontrolled type II diabetes mellitus. * Known chronic inflammatory conditions such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis), chronic pancreatitis, or autoimmune hepatitis, myositis, or myopathy. * History of asthma requiring medical treatment within 2 years prior to study entry with the exception of the use of albuterol inhaler for mild intermittent asthma. * Serious illness requiring systemic treatment and/or hospitalization within 14 days prior to entry. * Use of any of the following medications for more than 3 consecutive days within the 60 days prior to study entry: * Immunosuppressives (e.g., azathioprine, corticosteroids \[physiologic replacement doses are allowed\], cyclosporine, mycophenolate, NSAIDs (nonsteroidal anti-inflammatory drugs), sirolimus, sulfasalazine, tacrolimus) * Immune modulators (e.g., cytokines \[e.g., IL-2\], granulocyte colony stimulating factor, growth hormone, tumor necrosis factor antagonists, thalidomide) * Antineoplastic agents * Anticoagulants (e.g., warfarin and heparin) * Anti-platelet drugs (e.g., clopidogrel and aspirin) * Vaccinations within 1 week prior to the pre-entry or study entry visits. Routine standard of care vaccinations including hepatitis A and/or B, influenza, pneumococcal, and tetanus are permitted if administered at least 7 days before pre-entry and entry evaluations. * Participation on any HIV immunotherapy or therapeutic vaccination trials within 6 months prior to study entry. * Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * Use of investigational therapies within 30 days prior to study entry. * Rectal Tissue Subset only: * Abnormalities of the colorectal mucosa or significant colorectal symptom(s), which in the opinion of the study investigator represent a contraindication to biopsy (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids. * NOTE: Abnormalities of the colorectal mucosa will be assessed at the time of the enrollment flexible sigmoidoscopy. If no significant colorectal abnormalities or symptoms are present then the participant will undergo the enrollment procedures. If abnormalities are present then no biopsies will be performed and the participant will not be enrolled into the rectal tissue subset but will continue participation in the main study. * Active untreated gonorrhea, or chlamydia infection within 30 days prior to study entry (subjects diagnosed with rectal gonorrhea or chlamydia infection at screening may be treated during the screening period provided the treatment is at least 30 days prior to entry). * Exclusions for spirometry testing (for participants enrolled under Version 2.0) Participants will not undergo pre- and post-bronchodilator spirometry if they have any of the following: - Abdominal or cataract surgery within 3 months. * Myocardial infarction or stroke within the past 3 months. * Acute onset of shortness of breath, cough, fever or heart condition such as tachycardia, angina or arrhythmias with 4 weeks prior to enrollment. * Increasing respiratory symptoms or febrile (temperature \>100.4°F \[38°C\]) within 4 weeks of study entry. * Uncontrolled hypertension defined as systolic \> 160 mm Hg or diastolic \> 100 mm Hg from an average of two or more readings. Participant with controlled hypertension may undergo spirometry. * Prior history of adverse reaction to albuterol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12 | Baseline to week 12 | Change in plasma levels of sCD14 from baseline to week 12 |
| Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12 | baseline to week 12 | Change in Plasma levels of sCD163 from baseline to week 12 |
| Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12 | baseline to week 12 | Change in Plasma levels of IL-6 from baseline to week 12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Brachial Artery Flow-mediated Dilation (FMD) | Baseline to week 12 | To compare % change at tmax in brachial artery flow-mediated dilation (FMD) after 12 weeks of dipyridamole treatment to placebo |
| Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | Baseline to week 12 | To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing HLA-DR and CD38 after 12 weeks of DP treatment to placebo. |
| Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | Baseline to week 12 | To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing HLA-DR and CD38 after 12 weeks of Dipyridamole treatment to placebo. |
| Immune System Activation Assessed by the Proportion of CD4+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment to Placebo | Baseline to week 12 | To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo. |
| Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | Baseline to week 12 | To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo. |
| Systemic Inflammatory Biomarkers: Change in the Levels of sTNFαR | Baseline to week 12 | To compare changes in the levels of sTNFαR after 12 weeks of dipyridamole treatment to placebo |
| Systemic Inflammatory Biomarkers: Change in the Levels of TNFα | Baseline to week 12 | To compare changes in the levels of TNFα after 12 weeks of dipyridamole treatment to placebo |
| Systemic Inflammatory Biomarkers: Change in the Levels of hsCRP | Baseline to week 12 | To compare changes in the levels of hsCRP after 12 weeks of dipyridamole treatment to placebo |
| Coagulation Biomarkers: Change in the Levels of D-dimer | Baseline to week 12 | To compare changes in the levels of D-dimer after 12 weeks of dipyridamole treatment to placebo |
| Cellular Immune Activation: Change in the Proportion of Cycling CD8+ T Cells | Baseline to week 12 | To assess whether Dipyridamole reduces the proportion of cycling CD8+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole. |
| Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | First 12 weeks of dipyridamole treatment | Grade 2 or higher adverse events and treatment discontinuations |
| Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole | Baseline to week 12 | To assess whether Dipyridamole reduces the proportion of cycling CD4+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| ARM A: Dipyridamole for 24 Weeks Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24 | 21 |
| ARM B: Placebo for 12 Weeks, Then Dipyridamole for 12 Weeks Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24 | 19 |
| Total | 40 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 3 | 0 |
| Overall Study | Physician Decision | 2 | 1 |
| Overall Study | Protocol Violation | 1 | 1 |
Baseline characteristics
| Characteristic | ARM B: Placebo for 12 Weeks, Then Dipyridamole for 12 Weeks | ARM A: Dipyridamole for 24 Weeks | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 19 Participants | 21 Participants | 40 Participants |
| Age, Continuous | 50.0 years STANDARD_DEVIATION 6.9 | 48.4 years STANDARD_DEVIATION 11.2 | 49.2 years STANDARD_DEVIATION 9.3 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 2 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 19 Participants | 18 Participants | 37 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| IL-6 plasma levels | 1.77 pg/ml | 1.30 pg/ml | 1.48 pg/ml |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants | 3 Participants | 9 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 13 Participants | 15 Participants | 28 Participants |
| Region of Enrollment United States | 19 Participants | 21 Participants | 40 Participants |
| sCD14 plasma levels | 1754500.00 pg/ml | 1634000.00 pg/ml | 1695500.00 pg/ml |
| sCD163 plasma levels | 528.09 ng/ml | 478.81 ng/ml | 525.49 ng/ml |
| Sex: Female, Male Female | 4 Participants | 1 Participants | 5 Participants |
| Sex: Female, Male Male | 15 Participants | 20 Participants | 35 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 21 | 0 / 19 | 0 / 19 |
| other Total, other adverse events | 20 / 21 | 14 / 19 | 12 / 19 |
| serious Total, serious adverse events | 0 / 21 | 0 / 19 | 0 / 19 |
Outcome results
Primary
Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12
Change in plasma levels of sCD14 from baseline to week 12
Time frame: Baseline to week 12
Population: 35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12 | 244500.00 pg/ml |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12 | -58250.00 pg/ml |
p-value: 0.822Regression, Linear
Primary
Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12
Change in Plasma levels of sCD163 from baseline to week 12
Time frame: baseline to week 12
Population: 35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12 | -6.19 ng/ml |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12 | 5.42 ng/ml |
p-value: 0.0869Regression, Linear
Primary
Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12
Change in Plasma levels of IL-6 from baseline to week 12
Time frame: baseline to week 12
Population: 35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo); 4 Dipyridamole (1 adverse event 1 protocol deviation, 2 investigator discretion) and 1 placebo (change in antiretroviral therapy) participants were excluded from the primary AT analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12 | -0.02 pg/ml |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12 | -0.07 pg/ml |
p-value: 0.5027Regression, Linear
Secondary
Cellular Immune Activation: Change in the Proportion of Cycling CD8+ T Cells
To assess whether Dipyridamole reduces the proportion of cycling CD8+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole.
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Cellular Immune Activation: Change in the Proportion of Cycling CD8+ T Cells | -0.20 proportion of cycling CD8+ T Cells |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Cellular Immune Activation: Change in the Proportion of Cycling CD8+ T Cells | 0.05 proportion of cycling CD8+ T Cells |
p-value: 0.2343Mixed Models Analysis
Secondary
Changes in Brachial Artery Flow-mediated Dilation (FMD)
To compare % change at tmax in brachial artery flow-mediated dilation (FMD) after 12 weeks of dipyridamole treatment to placebo
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to DP after week 12.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Changes in Brachial Artery Flow-mediated Dilation (FMD) | 0.1 percentage change at tmax | Standard Deviation 5.2 |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Changes in Brachial Artery Flow-mediated Dilation (FMD) | -1.1 percentage change at tmax | Standard Deviation 4.8 |
p-value: 0.562Mixed Models Analysis
Secondary
Coagulation Biomarkers: Change in the Levels of D-dimer
To compare changes in the levels of D-dimer after 12 weeks of dipyridamole treatment to placebo
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Coagulation Biomarkers: Change in the Levels of D-dimer | 45.86 mcg/ml |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Coagulation Biomarkers: Change in the Levels of D-dimer | 36.35 mcg/ml |
p-value: 0.6121Mixed Models Analysis
Secondary
Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo
To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing HLA-DR and CD38 after 12 weeks of DP treatment to placebo.
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to DP after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | -0.25 proportion of CD4+ T cells |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | 0.10 proportion of CD4+ T cells |
p-value: 0.2075Mixed Models Analysis
Secondary
Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo
To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo.
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to DP after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | -0.05 proportion of CD8+ T cells |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | 0.00 proportion of CD8+ T cells |
p-value: 0.4548Mixed Models Analysis
Secondary
Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo
To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing HLA-DR and CD38 after 12 weeks of Dipyridamole treatment to placebo.
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | -0.85 proportion of CD8+ T cells |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | 0.25 proportion of CD8+ T cells |
p-value: 0.0315Mixed Models Analysis
Secondary
Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole
To assess whether Dipyridamole reduces the proportion of cycling CD4+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole.
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to DP after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole | -0.15 proportion of cycling CD4+ T Cells |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole | -0.05 proportion of cycling CD4+ T Cells |
p-value: 0.7556Mixed Models Analysis
Secondary
Immune System Activation Assessed by the Proportion of CD4+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment to Placebo
To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo.
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Immune System Activation Assessed by the Proportion of CD4+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment to Placebo | 0.00 proportion of CD4+ T cells |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Immune System Activation Assessed by the Proportion of CD4+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment to Placebo | 0.00 proportion of CD4+ T cells |
p-value: 0.7376Mixed Models Analysis
Secondary
Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations
Grade 2 or higher adverse events and treatment discontinuations
Time frame: First 12 weeks of dipyridamole treatment
Population: All enrolled participants
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | Grade 3 adverse events | 2 Participants |
| ARM A: Dipyridamole for 24 Weeks | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | Treatment discontinuations | 4 Participants |
| ARM A: Dipyridamole for 24 Weeks | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | No Grade 2 or 3 AEs or treatment discontinuations | 3 Participants |
| ARM A: Dipyridamole for 24 Weeks | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | Grade 2 adverse events | 12 Participants |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | No Grade 2 or 3 AEs or treatment discontinuations | 8 Participants |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | Grade 2 adverse events | 10 Participants |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | Grade 3 adverse events | 1 Participants |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | Treatment discontinuations | 0 Participants |
Secondary
Systemic Inflammatory Biomarkers: Change in the Levels of hsCRP
To compare changes in the levels of hsCRP after 12 weeks of dipyridamole treatment to placebo
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Systemic Inflammatory Biomarkers: Change in the Levels of hsCRP | -233.57 ng/dl |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Systemic Inflammatory Biomarkers: Change in the Levels of hsCRP | -750.35 ng/dl |
p-value: 0.3317Mixed Models Analysis
Secondary
Systemic Inflammatory Biomarkers: Change in the Levels of sTNFαR
To compare changes in the levels of sTNFαR after 12 weeks of dipyridamole treatment to placebo
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Systemic Inflammatory Biomarkers: Change in the Levels of sTNFαR | -84.61 pg/ml |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Systemic Inflammatory Biomarkers: Change in the Levels of sTNFαR | 34.26 pg/ml |
p-value: 0.7598Mixed Models Analysis
Secondary
Systemic Inflammatory Biomarkers: Change in the Levels of TNFα
To compare changes in the levels of TNFα after 12 weeks of dipyridamole treatment to placebo
Time frame: Baseline to week 12
Population: Per protocol, participants randomized to placebo were crossed over to Dipyridamole after week 12.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ARM A: Dipyridamole for 24 Weeks | Systemic Inflammatory Biomarkers: Change in the Levels of TNFα | -152.31 pg/ml |
| ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Systemic Inflammatory Biomarkers: Change in the Levels of TNFα | 123.88 pg/ml |
p-value: 0.983Mixed Models Analysis